KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Leases (2019 - 2026)

TherapeuticsMD filings provide 8 years of Leases readings, the most recent being $5.1 million for Q1 2026.

  • On a quarterly basis, Leases fell 14.9% to $5.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.1 million, a 14.9% decrease, with the full-year FY2025 number at $5.3 million, down 13.26% from a year prior.
  • Leases hit $5.1 million in Q1 2026 for TherapeuticsMD, down from $5.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $8.1 million in Q1 2022 to a low of $5.1 million in Q1 2026.
  • Median Leases over the past 5 years was $6.7 million (2024), compared with a mean of $6.6 million.
  • Biggest five-year swings in Leases: fell 7.65% in 2022 and later dropped 14.9% in 2026.
  • TherapeuticsMD's Leases stood at $7.6 million in 2022, then decreased by 9.33% to $6.9 million in 2023, then dropped by 11.22% to $6.1 million in 2024, then decreased by 13.26% to $5.3 million in 2025, then fell by 4.36% to $5.1 million in 2026.
  • The last three reported values for Leases were $5.1 million (Q1 2026), $5.3 million (Q4 2025), and $5.5 million (Q3 2025) per Business Quant data.